Parkinson’s Disease accounted for a 2.8% share of the global clinical trials within the Central Nervous System therapy area in 2021, registering a decrease of 0.2% when compared with the last ten-year average of 3.0% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials for Parkinson’s Disease
Industry sponsored trials held a 61.6% share of all the clinical trials for the Parkinson’s Disease indication in 2021, registering an increase of 9.3% when compared with the ten-year average of 52.3%. Non-industry sponsored trials accounted for a 38.4% share in 2021, marking a decrease of 9.3% over the ten-year average of 47.7%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Parkinson’s Disease trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Parkinson’s Disease trials, accounting for a 45.3% share in 2021, when compared with the five-year average of 35.4% and ten-year average of 32.0%.
Europe was at the second position with a 34.7% share in 2021, over the five-year average of 39.7% and ten-year average of 41.7%, followed by North America with a 26.7% share in 2021, as against five-year and ten-year averages of 47.2% and 44.6% respectively.
Middle East and Africa stood fourth with a 2.7% share in 2021, compared with the five-year average of 7.1% and ten-year average of 7.2%, followed by South and Central America with a 0.0% share in 2021, over five-year and ten-year averages of 1.6% and 1.8% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for industry sponsored Parkinson’s Disease trials, accounting for a 25.3% share in 2021, as against the five-year average of 13.0% and ten-year average of 8.9%.
The US held a 25.3% share in 2021, over the five-year average of 45.9% and ten-year average of 43.2%, followed by Spain with a 9.3% share in 2021, compared with the five-year and ten-year averages of 12.2% and 11.3% respectively.
Germany held a 9.3% share in 2021, as against the five-year average of 14.3% and ten-year average of 16.4%.
Japan held a 9.3% share in 2021, over the five-year and ten-year averages of 8.6% and 10.1% respectively.
Top regions of non-industry sponsored Parkinson’s Disease trials
Asia-Pacific was the top region for non-industry sponsored Parkinson’s Disease trials, accounting for a 45.7% share in 2021 when compared with the five-year average of 42.6% and ten-year average of 38.8%.
North America was at the second position with a 30.4% share in 2021, over the five-year and ten-year averages of 27.2% and 28.8% respectively, followed by Europe with a 17.4% share in 2021, as against the five-year average of 21.8% and ten-year average of 25.4%.
Middle East and Africa stood at the fourth position with a 6.5% share in 2021, compared with the five-year average of 8.0% and ten-year average of 6.6%, followed by South and Central America with a 0.0% share in 2021, over the five-year and ten-year averages of 1.5% and 1.6% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Parkinson’s Disease trials, accounting for a 30.4% share in 2021, as against the five-year average of 18.1% and ten-year average of 11.4%.
The US held a 26.1% share in 2021, over the five-year average of 23.9% and ten-year average of 24.9%, followed by Israel with a 4.3% share, compared with the five-year and ten-year averages of 0.3% and 0.9% respectively.
Italy held a 4.3% share in 2021, as against the five-year average of 2.4% and ten-year average of 3.5%.
South Korea held a 4.3% share in 2021, over the five-year average of 2.4% and ten-year average of 4.6%.
Phase I trials lead industry sponsored clinical trials for Parkinson’s Disease in 2021
Phase I trials held a 48.2% share of industry sponsored clinical trials for Parkinson’s Disease in 2021, over the five-year average of 50.6% and ten-year average of 46.4%.
Phase II trials held a 32.9% share in 2021, as against the five-year average of 32.5% and ten-year average of 26.7%. Phase III trials held a 10.6% share in 2021, compared with the five-year and ten-year averages of 9.6% and 16.2% respectively.
Phase IV trials held an 8.2% share in 2021, over the five-year average of 7.3% and ten-year average of 10.6%.
Phase II trials lead non-industry sponsored clinical trials for Parkinson’s Disease in 2021
Phase II trials held a 49.1% share of non-industry sponsored clinical trials for Parkinson’s Disease in 2021, over the five-year average of 53.3% and ten-year average of 54.9%.
Phase I trials held a 22.6% share in 2021, as against the five-year average of 16.6% and ten-year average of 14.0%. Phase IV trials held a 17.0% share, compared with the five-year and ten-year averages of 17.4% and 19.0% respectively.
Phase III trials held a 11.3% share in 2021, over the five-year average of 12.8% and ten-year average of 12.1%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
